| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LMP2 |
| Uniprot No | P13285 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-497aa |
| 氨基酸序列 | MGSLEMVPMGAGPPSPGGDPDGYDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPPYEDPYWGNGDRHSDYQPLGTQDQSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGSMNPVCLPVIVAPYLFWLAAIAASCFTASVSTVVTATGLALSLLLLAAVASSYAAAQRKLLTPVTVLTAVVTFFAICLTWRIEDPPFNSLLFALLAAAGGLQGIYVLVMLVLLILAYRRRWRRLTVCGGIMFLACVLVLIVDAVLQLSPLLGAVTVVSMTLLLLAFVLWLSSPGGLGTLGAALLTLAAALALLASLILGTLNLTTMFLLMLLWTLVVLLICSSCSSCPLSKILLARLFLYALALLLLASALIAGGSILQTNFKSLSSTEFIPNLFCMLLLIVAGILFILAILTEWGSGNRTYGPVFMCLGGLLTMVAGAVWLTVMSNTLLSAWILTAGFLIFLIGFALFGVIRCCRYCCYYCLTLESEERPPTPYRNTV |
| 预测分子量 | 54.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LMP2重组蛋白的3篇参考文献(示例为模拟内容，实际文献需根据具体研究补充)：
1. **"Expression and purification of recombinant LMP2 protein for EBV-related cancer immunotherapy"**
- **作者**: Smith J, et al.
- **摘要**: 研究利用大肠杆菌系统高效表达EB病毒潜伏膜蛋白LMP2的重组蛋白，优化纯化方法，并验证其在体外诱导特异性T细胞免疫反应的能力，为EBV相关肿瘤的免疫治疗提供候选抗原。
2. **"Structural and functional characterization of LMP2 in modulating MHC class I antigen presentation"**
- **作者**: Lee H, et al.
- **摘要**: 通过重组LMP2蛋白的晶体结构解析，揭示其与宿主细胞蛋白酶体相互作用的机制，阐明LMP2如何干扰MHC I类抗原呈递通路，进而帮助EB病毒逃逸免疫监视。
3. **"Recombinant LMP2-based vaccine induces protective immunity against EBV-associated lymphomas in a murine model"**
- **作者**: Zhang R, et al.
- **摘要**: 开发基于重组LMP2蛋白的疫苗，联合佐剂在小鼠模型中显著抑制EBV相关淋巴瘤的生长，证明其通过激活CD8+ T细胞和增强抗体反应发挥抗肿瘤作用。
如需具体文献，建议通过PubMed或Google Scholar以关键词“recombinant LMP2 protein”或“LMP2 EBV”检索近期研究。
**Background of LMP2 Recombinant Protein**
The LMP2 (Low Molecular Mass Protein 2) protein, also known as PSMB9 or β1i, is a catalytic subunit of the immunoproteasome, a specialized form of the 20S proteasome. Unlike constitutive proteasomes, immunoproteasomes are induced by interferon-gamma (IFN-γ) during inflammatory responses and play a critical role in antigen processing for major histocompatibility complex class I (MHC-I) presentation. LMP2 replaces the constitutive β1 subunit (PSMB6) in immunoproteasomes, altering cleavage specificity to generate peptides with hydrophobic or basic C-termini, which are optimal for MHC-I binding.
Recombinant LMP2 protein is engineered through molecular cloning, typically expressed in systems like *E. coli*, insect cells, or mammalian cells. This allows large-scale production of the protein for functional studies. Researchers utilize recombinant LMP2 to investigate immunoproteasome assembly, substrate processing, and its role in immune regulation. Dysregulation of LMP2 has been linked to autoimmune diseases (e.g., rheumatoid arthritis), cancer (altered antigen presentation), and neurodegenerative disorders, making it a therapeutic target.
Applications include *in vitro* enzymatic assays to study inhibitor efficacy, structural analysis (e.g., X-ray crystallography) to map active sites, and cell-based studies exploring immunoproteasome function in disease models. Recombinant LMP2 also aids in developing targeted therapies, such as immunoproteasome-specific inhibitors for autoimmune conditions or enhancers for cancer immunotherapy. Its study advances understanding of adaptive immunity and protein homeostasis mechanisms.
×
